Research Article
Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators
Table 2
Unadjusted and adjusted hazard ratios for all-cause mortality following PSA failure.
| Clinical factor | Number of men | Number of events | Univariable HR (95% CI) | | Multivariable AHR (95% CI) | |
| Treatment arm | | | | | | | Radiation | 35 | 16 | Ref. | — | Ref. | — | Radiation + ADT | 18 | 8 | 1.01 (0.43–2.37) | 0.99 | 1.69 (0.68–4.19) | 0.26 | Gleason | | | | | | | ≤7 | 45 | 18 | Ref. | — | Ref. | — | >7 | 8 | 6 | 2.02 (0.80–5.10) | 0.14 | 0.82 (0.28–2.44) | 0.72 | Clinical T category | | | | | | | T1 | 23 | 10 | Ref. | — | Ref. | — | T2 | 30 | 14 | 0.93 (0.41–2.13) | 0.87 | 0.65 (0.25–1.72) | 0.39 | ACE-27 comorbidity | | | | | | | None or minimal | 41 | 14 | Ref. | — | Ref. | — | Moderate or severe | 12 | 10 | 5.32 (2.31–12.3) | <0.001 | 12.50 (3.81–41.0) | <0.001 | Age in years at PSA failure | 53 | 24 | 1.12 (1.02–1.22) | 0.01 | 1.14 (1.03–1.25) | 0.008 | Interval to PSA failure in months* | 53 | 24 | 1.73 (0.75–3.98) | 0.20 | 2.36 (0.89–6.26) | 0.09 | PSA doubling time in months* | 53 | 24 | 0.98 (0.60–1.59) | 0.92 | 1.15 (0.63–2.08) | 0.66 |
|
|
Log-transformed. ADT: androgen deprivation therapy; PSA: prostate specific antigen.
|